ArticleTranslational oncology2026
SENP7 mediates deSUMOylation and deubiquitination of SP1 to promote lung adenocarcinoma progression and chemoresistance.
Article in Translational oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLung adenocarcinoma (LUAD) represents a significant global health challenge due to its elevated morbidity and mortality rates. Despite advancements in LUAD therapies, there remains an imperative need for novel therapeutic targets for patients who exhibit unresponsiveness or resistance to existing treatment modalities.
methodsTo investigate the potential role of SENP7 in LUAD progression, we analyzed SENP7 expression levels in LUAD and normal lung tissues using data from the TCGA, GTEx, and CPTAC databases, supplemented by immunohistochemistry (IHC) staining and western blotting assays. Additionally, the effects of SENP7 and SP1 on LUAD progression were assessed through CCK-8 assays, colony formation assays, EDU incorporation assays, and tumor xenograft experiments. To elucidate the role of the SENP7-SP1 pathway in LUAD progression, we conducted ubiquitination assays, co-immunoprecipitation (Co-IP), SUMOylation assays, and western blotting analyses.
resultsIn this study, we demonstrated that the SENP7 protein is markedly expressed in LUAD, with a strong correlation to disease progression and adverse patient prognoses. Our findings reveal that the depletion of SENP7 substantially impedes LUAD progression in both in vitro and in vivo models. Importantly, we identified SP1 as a bona fide target of SENP7, with SENP7-mediated deSUMOylation, deubiquitination, and stabilization of SP1 being essential for LUAD development and chemoresistance.
conclusionsThese results underscore the pivotal role of the SENP7-SP1 axis in promoting chemoresistance and disease progression in LUAD, thereby providing a foundation for potential therapeutic strategies in the management of advanced cancer.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.